Abstract: A conjugated or partially conjugated polymer comprising a structural unit of Formula I: I Wherein Ar1 is an aromatic group which contains one or more heteroatoms, or an aromatic group which comprises one or more fused aromatic or non-aromatic rings, said aromatic group may be substituted or unsubstituted; and R1 is alkyl, alkoxy, and aryl group, cyano, or F.

Abstract: The present invention provides fluorogenic compounds for the detection of target metal ions wherein the compounds exhibit a Stokes shift greater than 50 nm and the detectable signal is modulated by photoinduced electron transfer (PET). The present compounds consist of three functional elements, the ion sensing moiety (chelating moiety), the reporter moiety (fluorophore or fluorescent protein) and spacer or linker between the sensing and reporter moieties of the present compound that allows for PET upon binding of a metal ion and excitation by an appropriate wavelength.

Abstract: Provided are a phenylphenoxazine- or phenylphenothiazine-based compound and an organic electroluminescent device using the same. The phenylphenoxazine- or phenylphenothiazine-based compound is easily prepared, easily dissolved, and has excellent hole injection properties and excellent thermal stability. Accordingly, the compound is suitable for an organic layer of the organic electroluminescent device, specifically, a hole injection layer or a hole transport layer. In addition, the compound is suitable for an organic pigment or an electronic material, such as a nonlinear optical material.

Abstract: Disclosed are novel compounds of general formula (I) where the symbols are as defined in the specification, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. The compounds are useful in the treatment of diabetes and related diseases.

Abstract: The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic ?-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.

Abstract: A hydroxytetrahydrofuran of formula wherein A is with the substituents as defined in the specification, having a calpain inhibiting activity and/or an activity which traps the reactive oxygen species useful for treating inflammatory and immunological diseases, cardio-vascular and cerebro-vascular diseases, disorders of the central or peripheral nervous system, osteoporosis, muscular dystrophy, proliferative diseases, cataract, rejection reactions following organ transplants and autoimmune and viral diseases.

Abstract: A method of detecting platinum group metals in a sample is provided. The method comprises the step of contacting the sample with a fluorophore capable of undergoing allylic ether or allylic ester cleavage. The fluorophore has an oxygen-protected moiety, the protecting group having an allylic functionality. A reducing agent and optionally a solubilizer are also added to the sample. Very low levels of platinum group metals such as palladium and platinum can be detected in a sample.

Abstract: This invention provides caspase inhibitors of formula I: wherein Z is oxygen or sulfur; R1 is hydrogen, —CHN2, R, CH2OR, CH2SR, or —CH2Y; between R3 and R4 represents a single or double bond; Y is an electronegative leaving group; R2 is CO2H, CH2CO2H, or esters, amides or isosteres thereof; R3is a group capable of fitting into the S2 subsite of a caspase enzyme; R4 is a hydrogen or C1-6 alkyl or R3 and R4 taken together form a ring; Ring A and Ring B are each heterocyclic rings, and R and R5 are as described in the specification. The compounds are effective inhibitors of apoptosis and IL-1? secretion.

Abstract: Disclosed are compounds, compositions and methods for treating various diseases and conditions, including pain. Such compounds are represented by Formula I as follows: wherein A, G, Y, R3-R5 are defined herein.

Abstract: The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic ?-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.

Abstract: The present invention relates to novel enzymatic substrates with the following general formula: where R1, R2, R3, R4, R5, R6, A and X are as defined in claim 1, the reaction media comprising the same and the use thereof for the detection and/or identification and/or quantification of microorganisms expressing at least one peptidase activity.

Abstract: The present invention relates to crystalline R-guanidines of (2S)-2-Ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoate, its preparations and its use as therapeutic agents. More specifically the present invention relates to crystalline Arginine (2S)-2-Ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoate, preferably (L)-Arginine (2S)-2-Ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoate, its preparation and its use as therapeutic agent.

Abstract: The present invention provides fluorogenic probes and corresponding fluorescent compounds, methods of using the probes, compounds and kits that include the probes.

Abstract: A hydroxytetrahydrofuran of formula wherein A is with the substituents as defined in the specification, having a calpain inhibiting activity and/or an activity which traps the reactive oxygen species useful for treating inflammatory and immunological diseases, cardio-vascular and cerebro-vascular diseases, disorders of the central or peripheral nervous system, osteoporosis, muscular dystrophy, proliferative diseases, cataract, rejection reactions following organ transplants and autoimmune and viral diseases.

Abstract: The invention provides a compound, useful as an optical probe or sensor of the activity of at least one cytochrome P450 enzyme, and methods of using the compound to screen candidate drugs, and candidate drugs identified by these methods.

Abstract: Provided is an anthracene derivative compound represented by Formula 1 below and an organic light-emitting device using the same: wherein Ar1, Ar2, R1, R2, R?, m, n, j, k, and X are as defined in the specification. The anthracene derivative compound is advantageously used in the production of an organic light-emitting device with better driving voltage, efficiency, and color purity.

Abstract: Provided are a cyclopentaphenanthrene-based compound and an organoelectroluminescent device employing the same. The cyclopentaphenanthrene-based compound is easy to prepare and excellent in solubility, color purity, color stability, and thermal stability. The cyclopentaphenanthrene-based compound is useful as a material for forming an organic layer, in particular, an emitting layer, in an organoelectroluminescent device, and as an organic dye or an electronic material such as a nonlinear optical material.

Abstract: A cyclopentaphenanthrene-based compound is easy to prepare and excellent in solubility, color purity, color stability, and thermal stability. The cyclopentaphenanthrene-based compound is useful as a material for forming an organic layer, in particular, an emitting layer, in an organoelectroluminescent device, and as an organic dye or an electronic material such as a nonlinear optical material.

Abstract: A compound for use in electrochromic devices. The compound includes (1) ?-(10-phenothiazyl)propoxy phosphonic acid; (2) ?-(10-phenothiazyl)propyl-phosphonic acid; and (3) ?-(10-phenothiazyl)propionate phosphonic acid.

Abstract: A cyclopentaphenanthrene-based compound is easy to prepare and excellent in solubility, color purity, and color stability. The cyclopentaphenanthrene-based compound is useful as a material for forming an organic layer, in particular, an emitting layer, in an organoelectroluminescent device, and as an organic dye or an electronic material such as a nonlinear optical material.

Abstract: The present invention relates to a liquid crystal composition comprising a compound represented by the following formula (1) and a liquid crystal and a liquid crystal element containing the liquid crystal composition: wherein R1, R2, R3, R4, R5, R6 and R7 each independently represent a hydrogen atom or a substituent; and X represents an oxygen atom or a sulfur atom.

Abstract: The present invention relates to red color emitting compounds for an organic electroluminescent device (OELD), particularly to red color emitting compounds represented by the following formula (1) having high luminescence efficiency and enhanced thermal-stability: R1—CH?CH—X—CH?CH—R2 wherein, R1, R2 and X each are as defined below.

Abstract: It is an object to provide an organic compound that has a bipolar property and also a light emitting property, and further has heat resistance. A quinoxaline derivative represented by a general formula (1) is provided. In the formula, A represents any one of an alkylene chain, silicon (Si), oxygen (O), nitrogen (N), and sulfur (S). R1 to R8, which may be identical or different, individually represent any one of a lower alkyl group, an aryl group, and a heterocyclic group.

Abstract: Novel ?-aryl-?-oxysubstituted alkylcarboxylic acids of the formula (I) and compositions containing them. The compounds have hypolipidemic, antihyperglycemic uses.

Abstract: Dye reagents useful in labeling biological materials are provided along with methods for their use.

Abstract: A compound represented by formula (I); a process for producing a compound (substance F-1490) of formula (I), wherein X represents —O— and R represents a hydroxyl group, by using a microorganism belonging to the genus Cunninghamella; and a Cunninghamella sp. F-1490 strain (FERM BP-8287) capable of producing the substance F-1490; and an osteoclast differentiation inhibitory agent containing as an active ingredient the compound represented by formula (I): wherein X represents —O— or —CH2—, and R represents a hydroxyl group when X represents —O—, or a hydrogen atom when X represents —CH2—.

Abstract: The present invention provides compounds of formula (I) the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers, and prodrugs; wherein R1, R2, Ra, Rb, X, and Z are as defined herein; pharmaceutical compositions thereof; and uses thereof.

Abstract: An organic electroluminescence element comprising: an anode layer, a cathode layer, and an organic luminescence layer therebetween, the organic luminescence layer having a carbazole derivative with a glass-transition temperature of 110° C. or higher, and a phosphorescent dopant. This structure makes it possible to provide an organic electroluminescence element which can make use of the triplet exciton state of the carbazole derivative even at room temperature and which has a practical life and superior heat-resistance.

Abstract: A biphenyl derivative having an amino group with or without alkoxy substituent in the biphenyl backbone, and an organic electroluminescent device using the same.

Abstract: A composition of matter is disclosed wherein the composition comprises an N-aromatic substituted acid amide compound selected from the group consisting of compounds of formula (I) wherein A and B are independently selected alkylene groups; R1 is selected from the group consisting of hydrogen, alkyl, alkylether, or ester; R2 is hydrogen if R1 is hydrogen; R2 is an alkyl primary amine if R1 is alkyl, alkylether, or ester; R3 and R4 are independently selected from the group consisting of hydrogen and alkyl; R5 is a sterically hindered phenolic group of formula (II) or formula (III) wherein X is CH2, S, NH, or O; and m, n, and p are independently selected integers equal to 0 or 1. These compositions may be used as such or they may be bound to a polymer backbone via a linking moiety.

Abstract: The present invention relates to pharmaceutically acceptable salts of compound of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.

Abstract: The invention concerns compounds of the general formula (I) in which the residues R1 to R7 have the meanings given in the application as well as methods for their preparation.

Abstract: A blue electroluminescent compound and an organic electroluminescent device using the blue electroluminescent compound, which includes a 9,10-diphenyl anthracene unit in its backbone and has alkoxy groups and substituted or unsubstituted amino group introduced to the 2 and 5 positions on the phenyl group in the diphenyl anthracene unit.

Abstract: A biphenyl derivative having an amino group with or without alkoxy substituent in the biphenyl backbone, and an organic electroluminescent device using the same.

Abstract: The present invention provides a compound of the formula and pharmaceutically acceptable salts having useful antiviral activity against viruses of the herpes family. Wherein: X=O, (CH2)m, S, SO, SO2, NH, NR8; Y=O, (CH2)m, S, SO, SO2, NH, NR8 or a chemical bond; Z=NH, O, NR8, S, SO, SO2; The remaining substituents are described in the specification.

Abstract: The present invention concerns prodrugs whose aromatic oxidation, particularly their enzymatic aromatic hydroxylation, results in their activation by the release of a drug moiety. It particularly concerns anti-tumor prodrugs and those which are specifically activated by the hydroxylation activity of the P-450 enzyme CYP1B1. Also provided are methods of detection of aromatic oxidation activity.

Abstract: A blue electroluminescent compound and an organic electroluminescent device using the blue electroluminescent compound, which includes a 9,10-diphenyl anthracene unit in its backbone and has alkoxy groups and substituted or unsubstituted amino group introduced to the 2 and 5 positions on the phenyl group in the diphenyl anthracene unit.

Abstract: The present invention relates to red color emitting compounds for an organic electroluminescent device (OELD), particularly to red color emitting compounds represented by the following formula (1) having high luminescence efficiency and enhanced thermal-stability:

Abstract: Disclosed are compounds of the formula and the pharmaceutically acceptable salts thereof wherein R, Ar, A, n, R1 and R2 are defined herein. These compounds are highly selective agonists, antagonists or inverse agonists for GABAA brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAA brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Down Syndrome, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are also disclosed.

Abstract: The present application describes novel cyclic hydroxamic acids of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NR1, and S(O)p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), aggrecanase or a combination thereof, pharmaceutical compositions containing the same, and methods of using the same.

Abstract: N-(imino)amines and their preparation and their use as NO synthase inhibitors and selective or non-selective traps for a reactive oxygen species.

Abstract: The present invention relates to marking a petroleum product with a silent marker, which is an ester derivative of fluorescent material, and to detecting the same. In accordance with the present invention, the silent marker may be detected by measuring the fluorescence generated from the selective hydrolysis of the ester moiety under enzymatic action.

Abstract: Benzopiperidine derivatives represented by formula (I), salts thereof or hydrates thereof, processes for producing the same and drugs comprising the same: 1

Abstract: This invention relates to compounds represented by the general formula [I] 1

Abstract: This invention relates to a compound and the use of the compound of the formula wherein R1, R2, R3, R4 and R5 are as defined in the description, A signifies —CH═CH— or —C≡C—; and B signifies wherein R6 to R26, X and Y are as defined in the specification or a pharmaceutically acceptable salt thereof, for use in pharmaceutical compositions for the treatment or prevention of mGluR5 receptor mediated disorders.

Abstract: The present invention relates to compounds of the general formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by clear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

Abstract: The present invention provides a compound of the formula (I) and pharmaceutically acceptable salts having useful antiviral activity against viruses of the herpes family. In said formula, X=O, (CH2)m, S, SO, SO2, NH, NR8 or a chemical bond; Y=O, (CH2)m, S, SO, SO2, NH, NR8; Z=NH, O, NR8, S, SO, SO2. The remaining substituents are described in the specification.

Abstract: The present invention relates to compounds of the general formula (I) 1

Abstract: Acetyl Coenzyme A Carboxylase inhibitors, pharmaceutical compositions containing such compounds and the use of such compounds to treat for example, Metabolic Syndrome including atherosclerosis, diabetes and obesity.

Abstract: A phenothiazine, acridan, acridone oxime, acridone hydrazone and dibenzodiazepine derivative represented by formula (I) 1